MammaPrint + BluePrint work together to clarify the complexity of overall early-stage breast cancer treatment strategy for each individual patient.
Rely on definitive results with the most comprehensive genomic profile for breast cancer that includes molecular subtyping. With specific guidance, confidently optimize neoadjuvant, adjuvant, or extended adjuvant therapy for each patient, including those that are clinically high-risk. Find clarity every step of the way at agendia.com
MammaPrint, our FDA-cleared test backed by the highest level of clinical evidence, paired with BluePrint, the only commercially available molecular subtyping test, enable you to confidently optimize a unique treatment strategy for each patient.

• Neoadjuvant chemotherapy
• Neoadjuvant endocrine therapy
• Adjuvant chemotherapy
• No adjuvant chemotherapy
• No extended endocrine therapy

Identify unique molecular subtypes through BluePrint (80-gene assay)

• Determines patients who may benefit from neoadjuvant chemotherapy with an increased likelihood of pathologic complete response (pCR) to inform surgery decisions
• Reveals the 1 in 5 ER+ patients with basal-type breast cancer who may benefit from treatment similar to treatment for triple negative breast cancer
• Identifies patients who may have little response to chemotherapy and may respond to neoadjuvant endocrine therapy

Optimize treatment strategy through MammaPrint (70-gene assay)

• Predicts chemosensitivity – MammaPrint High Risk results associated with increased likelihood of pCR
• Demonstrates a consistent relative benefit of chemotherapy across clinical trials in MammaPrint High Risk patients (40-50%),
• Reclassifies 46% of clinically high risk patients as MammaPrint Low Risk, who may safely avoid chemotherapy
• Identifies patients with an Ultralow Risk of late recurrence (20 yrs) unlikely to benefit from extended endocrine therapy beyond 5 years

Definitive results for more of your patients with MammaPrint + BluePrint

• Results unaffected by age, pre- or postmenopausal, hormone receptor and nodal status, race, ethnicity, or metabolic syndrome
• The 70-gene assay (MammaPrint®) is the only genomic test with a category 1 National Comprehensive Cancer Network® (NCCN®) recommendation in both LN- and LN+ (0-3 lymph nodes) patients with hormone receptor positive and HER2-negative early stage breast cancer*
• Reports the continuous score as a binary result
• Enables faster decision-making and less patient anxiety with quick turnaround time and user-friendly results
• Developed independently of clinicopathologic factors in untreated patients
• Identifies genes and pathways involved in metastatic recurrence through unbiased gene selection

Experts recommend use of a single comprehensive genomic profile to inform treatment decisions.
Choose MammaPrint + BluePrint to optimize treatment strategy for your patients. Visit agendia.com/everywoman